Optimizing Adeno-Associated Virus Loading Amounts for Host Cell Protein Analysis

Importance of the topic

Adeno-associated virus (AAV) vectors have become central to cell and gene therapies, but their low yields pose challenges for host cell protein (HCP) impurity profiling. Reliable detection and quantitation of HCPs are critical for ensuring product safety and stability, while minimizing sample consumption is essential when working with limited AAV material.

Study objectives and overview

This application note evaluates the trade-off between AAV injection load and HCP detection sensitivity using LC/Q-TOF mass spectrometry. Three injection levels (50 %, 33 %, 12.5 % of a 4.75 × 10¹² VP/mL standard) were compared to determine the minimum sample amount required to detect low-level HCPs below the typical 1 ppm threshold.

Methodology and instrumentation

The AAV1 empty capsid standard (4.75 × 10¹² VP/mL) was denatured, reduced, alkylated, and digested overnight with a Lys-C/trypsin mix. Samples were dried, reconstituted, and spiked with lysozyme (100 ppm) and cytochrome C (10 ppm) as internal controls.

• Liquid chromatography: Agilent 1290 Infinity II with AdvanceBio Peptide Plus column (2.1 × 150 mm) at 50 °C, 0.4 mL/min, gradient from 3 % to 40 % B over 90 min.
• Mass spectrometry: Agilent 6545XT AdvanceBio LC/Q-TOF with Dual Agilent Jet Stream, Auto MS/MS acquisition at 5/3 spectra/sec, reference masses 121.0509 and 922.0098 m/z, calibrated by SWARM.
• Data analysis: Protein Metrics Byos software with SwissProt human proteome database.

Key results and discussion

High in-spectrum dynamic range (>5 orders of magnitude) enabled confident identification of low-abundance peptides with mass errors under 1 ppm. Coelution experiments demonstrated that even peptides more than 30-times less abundant than AAV capsid signals could be resolved with sharp peaks (tailing factor ~1.08).

Injection A (50 %) detected HCPs down to 300 ppb and yielded the greatest protein count, including six proteins not seen at lower loads. Injection B (33 %) identified HCPs as low as 500 ppb, while Injection C (12.5 %) fell below the detection threshold. Neither injection revealed any high-risk, immunogenic, or enzymatically active HCPs on established risk lists.

Benefits and practical applications

This workflow provides a sensitive, MS-based orthogonal assay for HCP profiling in AAV samples with minimal material consumption. It supports quality control for gene therapy products, enabling labs to balance detection limits with sample availability.

Future trends and potential applications

Emerging developments include automated sample preparation (e.g., AssayMAP Bravo), iterative MS/MS acquisition for deeper coverage, and unbiased identification workflows. Extending this approach to other viral vectors and bioprocess monitoring will further advance biologics analytics.

Conclusion

The optimized LC/Q-TOF method using the AdvanceBio Peptide Plus column reliably detects HCPs below 1 ppm at injection loads of 33 %–50 % of AAV standard. This balance offers robust sensitivity while conserving precious viral material.

References

1. U.S. Food and Drug Administration. Human Gene Therapy for Neurodegenerative Diseases. FDA Guidance (2023).
2. Jones M. et al. "High-risk" Host Cell Proteins (HCPs): A Multi-company Collaborative View. Biotechnol. Bioeng. 118(8), 2870–2885 (2021).
3. Wu L., Wu S., Chu W. Host Cell Protein Analysis Using Agilent AssayMAP Bravo and 6545XT AdvanceBio LC/Q-TOF. Agilent Technologies Application Note 5991-9300EN (2023).
4. Huang Y. et al. Toward Unbiased Identification and Comparative Quantification of HCP Impurities by Automated Iterative LC–MS/MS. J. Pharm. Biomed. Anal. 200, 114069 (2021).
5. Pilely K. et al. Monitoring Process-Related Impurities in Biologics–HCP Analysis. Anal. Bioanal. Chem. 414(2), 747–758 (2022).
6. Rumachik N.G. et al. Methods Matter: Standard Production Platforms for Recombinant AAV Produce Chemically and Functionally Distinct Vectors. Mol. Ther. Methods Clin. Dev. 18, 98–118 (2020).